Filing Details
- Accession Number:
- 0001209191-24-005486
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-02 21:27:45
- Reporting Period:
- 2024-05-01
- Accepted Time:
- 2024-05-02 21:27:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1607678 | Viking Therapeutics Inc. | VKTX | Pharmaceutical Preparations (2834) | 461073877 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1838112 | Marianna Mancini | C/O Viking Therapeutics, Inc. 9920 Pacific Heights Blvd, Suite 350 San Diego CA 92121 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2024-05-01 | 17,999 | $4.68 | 366,507 | No | 4 | M | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2024-05-01 | 87,000 | $4.88 | 453,507 | No | 4 | M | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2024-05-01 | 90,000 | $5.80 | 543,507 | No | 4 | M | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2024-05-01 | 35,426 | $7.77 | 578,933 | No | 4 | M | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2024-05-01 | 51,000 | $8.52 | 629,933 | No | 4 | M | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Disposition | 2024-05-01 | 23,746 | $76.40 | 606,187 | No | 4 | S | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Disposition | 2024-05-01 | 26,142 | $77.49 | 580,045 | No | 4 | S | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Disposition | 2024-05-01 | 105,343 | $78.65 | 474,702 | No | 4 | S | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Disposition | 2024-05-01 | 119,946 | $79.29 | 354,756 | No | 4 | S | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Disposition | 2024-05-01 | 6,248 | $80.08 | 348,508 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-05-01 | 17,999 | $0.00 | 17,999 | $4.68 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-05-01 | 87,000 | $0.00 | 87,000 | $4.88 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-05-01 | 90,000 | $0.00 | 90,000 | $5.80 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-05-01 | 35,426 | $0.00 | 35,426 | $7.77 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-05-01 | 51,000 | $0.00 | 51,000 | $8.52 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1 | 2021-03-31 | 2030-03-31 | No | 4 | M | Direct |
| 87,000 | 2023-01-03 | 2032-01-03 | No | 4 | M | Direct |
| 0 | 2022-01-04 | 2031-01-04 | No | 4 | M | Direct |
| 18,574 | 2021-01-03 | 2030-01-03 | No | 4 | M | Direct |
| 153,000 | 2024-01-03 | 2033-01-03 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 1, 2024.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $76.09 to $76.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $77.00 to $77.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $78.00 to $78.9983, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.00 to $79.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $80.02 to $80.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date.
- One-third of the shares subject to the option vested on each one year anniversary of the grant date.
Billionaire Hedge Funds
